Search

Your search keyword '"Pancreatic cancer -- Conferences, meetings and seminars"' showing total 222 results
Start Over Descriptor "Pancreatic cancer -- Conferences, meetings and seminars"
222 results on '"Pancreatic cancer -- Conferences, meetings and seminars"'

201. Specialised Therapeutics Australia: Updated Pancreatic Cancer Data Presented at International Cancer Conference

Subjects
Clinical trials -- Conferences, meetings and seminars, Pancreatic cancer -- Conferences, meetings and seminars, Business, News, opinion and commentary, American Society of Clinical Oncology -- Conferences, meetings and seminars, Abraxane (Medication)
Abstract

MELBOURNE, Australia, Jan. 17, 2014 /PRNewswire/ -- * Study shows ABRAXANE plus gemcitabine combination therapy further extends overall survival benefit * First Phase III trial in metastatic pancreatic cancer to [...]

Published
2014

202. OncoMed Pharmaceuticals Presents Data From the Phase 1b Portion of the ALPINE Clinical Study of OMP-59R5 in Pancreatic Cancer at the 2014 Gastrointestinal Cancers Symposium

Subjects
Oncology, Experimental -- Conferences, meetings and seminars, Clinical trials -- Conferences, meetings and seminars, Cancer -- Research, Pancreatic cancer -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business, Abraxane (Medication)
Abstract

SAN FRANCISCO, Jan 17, 2014 (GLOBE NEWSWIRE via COMTEX) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today [...]

Published
2014

203. OncoMed Pharmaceuticals Presents Data From Demcizumab Phase 1b Clinical Study in Pancreatic Cancer at the 2014 Gastrointestinal Cancers Symposium

Subjects
Celgene Corp. -- Conferences, meetings and seminars, Oncology, Experimental -- Conferences, meetings and seminars, Clinical trials -- Conferences, meetings and seminars, Cancer -- Research, Pancreatic cancer -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business, Abraxane (Medication)
Abstract

SAN FRANCISCO, Jan 17, 2014 (GLOBE NEWSWIRE via COMTEX) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, presented [...]

Published
2014

204. Byetta Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Litigation for Byetta Lawsuits, Other Incretin Mimetic Claims

Subjects
United States. Food and Drug Administration -- Conferences, meetings and seminars, Diabetes therapy -- Conferences, meetings and seminars, Hypoglycemic agents -- Conferences, meetings and seminars, Liability (Law) -- Conferences, meetings and seminars, Pancreatic cancer -- Conferences, meetings and seminars, Business, general, Byetta (Medication)
Abstract

New York, New York (PRWEB) November 08, 2013 Byetta lawsuits (http://www.byettalawsuit2013.com/) and other product liability claims involving the use of diabetes drugs known as incretin mimetics continue to move forward [...]

Published
2013

205. OncoMed Pharmaceuticals Presents Data From Clinical Trials of Four Novel Anti-Cancer Stem Cell (Anti-CSC) Therapeutics at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, October 19-23, 2013

Subjects
Bayer HealthCare Pharmaceuticals -- Conferences, meetings and seminars, Stem cells -- Conferences, meetings and seminars, Clinical trials -- Conferences, meetings and seminars, Chemotherapy -- Conferences, meetings and seminars, Cancer -- Chemotherapy, Pancreatic cancer -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business
Abstract

REDWOOD CITY, Calif., Oct 21, 2013 (GLOBE NEWSWIRE via COMTEX) -- First Presentation of First-in-Human Trial of Anti-Notch1 (OMP-52M51) Suggests This Antibody Can be Given Safely With Early Suggestion of [...]

Published
2013

206. Victoza safety profile further supported at scientific workshop on pancreatitis, diabetes and pancreatic cancer

Subjects
United States. National Institute of Diabetes and Digestive and Kidney Diseases -- Safety and security measures -- Conferences, meetings and seminars, United States. National Cancer Institute -- Safety and security measures -- Conferences, meetings and seminars, United States. Food and Drug Administration -- Safety and security measures -- Conferences, meetings and seminars, Novo Nordisk A/S -- Safety and security measures -- Conferences, meetings and seminars, Diabetes -- Conferences, meetings and seminars, Pancreatitis -- Conferences, meetings and seminars, Workshops (Educational programs) -- Conferences, meetings and seminars, Pancreatic cancer -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Business, Chemicals, plastics and rubber industries, Victoza (Medication)
Abstract

On 13 Jun 2013, Novo Nordisk presented data further supporting the safety of Victoza (liraglutide [rDNA origin] injection) at a scientific workshop in the US arranged by the National Institute [...]

Published
2013

207. Victoza (liraglutide [rDNA origin] injection) safety profile further supported at scientific workshop on pancreatitis, diabetes and pancreatic cancer

Subjects
United States. Food and Drug Administration -- Safety and security measures -- Conferences, meetings and seminars, Diabetes -- Conferences, meetings and seminars, Pancreatitis -- Conferences, meetings and seminars, Workshops (Educational programs) -- Conferences, meetings and seminars, Pancreatic cancer -- Conferences, meetings and seminars, Business, News, opinion and commentary, Victoza (Medication)
Abstract

BAGSVAERD, Denmark and PLAINSBORO, N.J., June 13, 2013 /PRNewswire/ -- Today, Novo Nordisk presented data further supporting the safety of Victoza (liraglutide[rDNA origin] injection) at a scientific workshop in the [...]

Published
2013

208. Oncolytics Biotech[R] Inc. Collaborators Present Positive REOLYSIN[R] Trial Results and Research at EORTC-NCI-AACR Symposium

Subjects
Biotechnology -- Conferences, meetings and seminars, Biotechnology industry -- Conferences, meetings and seminars, Clinical trials -- Conferences, meetings and seminars, Lung cancer, Non-small cell -- Conferences, meetings and seminars, Pancreatic cancer -- Conferences, meetings and seminars, Business, News, opinion and commentary
Abstract

CALGARY, Nov. 9, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ('Oncolytics')(TSX:ONC, NASDAQ:ONCY) today announced three poster presentations covering expanded results from: a Phase II clinical trial using intravenous administration of REOLYSIN [...]

Published
2012

209. 15-YEAR-OLD SCIENTIFIC WHIZ KID DISCUSSES BREAKTHROUGH PANCREATIC CANCER SCREENING AT THE 2012 ASCP ANNUAL MEETING

Subjects
Cancer -- Diagnosis, Pancreatic cancer -- Conferences, meetings and seminars, News, opinion and commentary, Johns Hopkins University -- Conferences, meetings and seminars
Abstract

CHICAGO, Ill. -- The following information was released by the American Society for Clinical Pathology: His mentor at Johns Hopkins University, Baltimore, calls him the Thomas Edison of the 21st [...]

Published
2012

210. Clinical Study Results Presented at the 2015 Gastrointestinal Cancer Symposium Support Utility of Trovagene's Precision Cancer Monitoring Platform in Colorectal and Pancreatic Cancer Patients

Subjects
Conferences, meetings and seminars, Clinical trials -- Conferences, meetings and seminars, Cancer -- Conferences, meetings and seminars, Pancreatic cancer -- Conferences, meetings and seminars, Cancer research -- Conferences, meetings and seminars, Gastrointestinal cancer -- Conferences, meetings and seminars
Abstract

By a News Reporter-Staff News Editor at Clinical Trials Week -- Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced the presentation of results from two clinical studies [...]

Published
2015

211. Kalos Therapeutics Data Confirming Anti-Cancer Effect of Naturally Occurring Heart Hormones Presented at Experimental Biology 2008 Symposium

Subjects
Pancreatic cancer -- Conferences, meetings and seminars, Pancreatic cancer -- Drug therapy, Natriuretic peptides -- Conferences, meetings and seminars, Cancer -- Care and treatment, Cancer -- Conferences, meetings and seminars, Business, Business, international, University of South Florida -- Conferences, meetings and seminars
Abstract

New Findings Extend Previous Results in Pancreatic Cancer Xenograft Models SAN DIEGO -- Kalos Therapeutics, a privately held biopharmaceutical company developing the Atrial Natriuretic Peptide (ANP) family for the treatment [...]

Published
2008

212. pSivida's BrachySil(TM) in Pancreatic Cancer Study Results to be presented at the ASCO Gastrointestinal Cancers Symposium

Subjects
Pancreatic cancer -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Oncology, Experimental -- Conferences, meetings and seminars, Cancer -- Research, Cancer -- Conferences, meetings and seminars, Business, Business, international
Abstract

BOSTON & PERTH, Australia -- pSivida Limited (NASDAQ: PSDV)(ASX: PSD)(FF: PSI), a global drug delivery company, today announced that the final results of the recently completed Phase IIa Study of [...]

Published
2008

213. CancerVax Presents Preclinical Data Demonstrating Tumor Inhibition by D93, a Novel Anti-Angiogenic Monoclonal Antibody; Data Presented at AACR Annual Meeting

Subjects
CancerVax Corp. -- Conferences, meetings and seminars -- Product development, Taxol (Medication) -- Product development, Biological products industry -- Conferences, meetings and seminars -- Product development, Antineoplastic agents -- Conferences, meetings and seminars -- Product development, Monoclonal antibodies -- Conferences, meetings and seminars, Pancreatic cancer -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars -- Product development
Abstract

CARLSBAD, CA, Apr 04, 2006 (MARKET WIRE via COMTEX) -- CancerVax Corporation (NASDAQ: CNVX) announced today that its wholly owned subsidiary, Cell-Matrix, Inc., presented preclinical data indicating that D93, the […]

Published
2006

214. TransMolecular Presents New Data Highlighting the Anti-angiogenic and Tumor-targeting Properties of TM601 at ASCO Annual Meeting

Subjects
TransMolecular Inc. -- Conferences, meetings and seminars, Conferences, meetings and seminars, Gliomas -- Conferences, meetings and seminars, Neovascularization -- Conferences, meetings and seminars, Pancreatic cancer -- Conferences, meetings and seminars, Medical research -- Conferences, meetings and seminars, Biotechnology industries -- Conferences, meetings and seminars, Melanoma -- Conferences, meetings and seminars, Non-small cell lung cancer -- Conferences, meetings and seminars, Cancer metastasis -- Conferences, meetings and seminars, Medicine, Experimental -- Conferences, meetings and seminars, Metastasis -- Conferences, meetings and seminars, Biotechnology industry -- Conferences, meetings and seminars, Lung cancer, Non-small cell -- Conferences, meetings and seminars
Abstract

TransMolecular, Inc. announced new data highlighting the anti-angiogenic and tumor-targeting properties of TM601 in a poster presentation and in a published abstract at the 45th Annual Meeting of the American [...]

Published
2009

215. pSivida's BrachySil(TM) in Pancreatic Cancer Study Results to be presented at the ASCO Gastrointestinal Cancers Symposium

Subjects
Conferences, meetings and seminars, Stomach cancer -- Conferences, meetings and seminars, Pancreatic cancer -- Conferences, meetings and seminars, Cancer research -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Oncology, Experimental -- Conferences, meetings and seminars, Cancer -- Research
Abstract

pSivida Limited (NASDAQ: PSDV)(ASX: PSD)(FF: PSI), a global drug delivery company, announced that the final results of the recently completed Phase IIa Study of BrachySil(TM) for the treatment of inoperable [...]

Published
2008

216. Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference (ECCO)

Subjects
Conferences, meetings and seminars, Clinical trials -- Conferences, meetings and seminars, Pancreatic cancer -- Conferences, meetings and seminars
Abstract

Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), announced that results from a Phase 2 trial of glufosfamide plus gemcitabine were presented at the European Cancer Conference (ECCO) annual meeting in Barcelona, Spain (see [...]

Published
2007

217. Glufosfamide Results From Phase 3 Clinical Trial Presented at European Cancer Conference (ECCO)

Subjects
Conferences, meetings and seminars, Clinical trials -- Conferences, meetings and seminars, Pancreatic cancer -- Conferences, meetings and seminars, Cancer metastasis -- Conferences, meetings and seminars, Metastasis -- Conferences, meetings and seminars
Abstract

Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), announced that detailed results from a Phase 3 trial of glufosfamide were presented at the European Cancer Conference (ECCO) annual meeting in Barcelona, Spain (see also [...]

Published
2007

218. Pancreatic Cancer Action Network partners to organize public awareness symposium in New York

Subjects
Public relations, Conferences, meetings and seminars, Company public relations, Cancer treatment -- Conferences, meetings and seminars, Pancreatic cancer -- Conferences, meetings and seminars, Cancer -- Care and treatment
Abstract

Despite its ranking as the fourth cause of cancer death in the U.S., federal research funding on pancreatic cancer topped out last year at $66 million, or 1% of the [...]

Published
2006

219. Pancreatic Cancer Action Network partners to organize public awareness symposium in New York

Subjects
Public relations, Conferences, meetings and seminars, Company public relations, Cancer treatment -- Conferences, meetings and seminars, Pancreatic cancer -- Conferences, meetings and seminars, Cancer -- Care and treatment
Abstract

Despite its ranking as the fourth cause of cancer death in the U.S., federal research funding on pancreatic cancer topped out last year at $66 million, or 1% of the [...]

Published
2006

220. Pancreatic Cancer Action Network partners to organize public awareness symposium in New York

Subjects
Public relations, Conferences, meetings and seminars, Company public relations, Cancer treatment -- Conferences, meetings and seminars, Pancreatic cancer -- Conferences, meetings and seminars, Cancer -- Care and treatment
Abstract

Despite its ranking as the fourth cause of cancer death in the U.S., federal research funding on pancreatic cancer topped out last year at $66 million, or 1% of the [...]

Published
2006

221. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting

Author

Hasty, Susan

Subjects
Diseases, Conferences, meetings and seminars, Pancreatic cancer -- Conferences, meetings and seminars, Cancer research -- Conferences, meetings and seminars, Associations -- Conferences, meetings and seminars, Cancer metastasis -- Conferences, meetings and seminars, Oncology, Experimental -- Conferences, meetings and seminars, Societies -- Conferences, meetings and seminars, Metastasis -- Conferences, meetings and seminars, Cancer -- Research, Associations, institutions, etc. -- Conferences, meetings and seminars
Abstract

2008 APR 21 -- (NewsRx.com)--Oncothyreon Inc. (NASDAQ: ONTY) (TSX:ONY) announced that data from preclinical studies of PX-478, pharmacodynamic studies of PX-12 and preclinical studies of PX-866 will be presented at [...]

Published
2008

222. Avantogen Ltd., of Sydney, Australia, and Innovate Oncology Inc., of New York, said pancreatic cancer results on RP101 reported at the International Conference on Tumor Progression and Therapeutic Resistance in Burlington Mass., showed that the product extends survival beyond previous results of RP101 co-administered with standard chemotherapy

Subjects
Pancreatic cancer -- Conferences, meetings and seminars, Pancreatic cancer -- Health aspects, Company earnings/profit, Biotechnology industry, Business, Business, international
Abstract

Avantogen Ltd., of Sydney, Australia, and Innovate Oncology Inc., of New York, said pancreatic cancer results on RP101 reported at the International Conference on Tumor Progression and Therapeutic Resistance in [...]

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results